Pomerantz Law Firm Alerts Investors about Class Action Against BioAge Labs, Inc.

Pomerantz Law Firm Alerts Investors about Class Action Against BioAge Labs, Inc. – Key Deadlines Approaching

Investor Alert: Class Action Against BioAge Labs

Pomerantz LLP, a renowned law firm, has recently announced a class action lawsuit against BioAge Labs, Inc. (NASDAQ: BIOA) in response to significant losses suffered by investors. This legal action stems from allegations of possible securities fraud, raising questions about the company's business practices.

Background of the Lawsuit

The class action lawsuit primarily concerns the events surrounding the initial public offering (IPO) conducted by BioAge on September 26, 2024. The company sold 12.65 million shares at an initial price of $18.00 each. However, the situation took a dramatic turn when, on December 6, 2024, BioAge disclosed that it would terminate the Phase 2 STRIDES study of its investigational drug azelaprag due to serious side effects observed in some participants.

This announcement triggered a massive drop in BioAge's stock value, which plummeted by $15.44 per share—or approximately 76.85%—closing at just $4.65 per share by December 9, 2024.

How to Participate in the Class Action

Investors who are eligible to join this class action are those who purchased or acquired BioAge securities during the specified Class Period. To take part, individuals must motion to the court by March 10, 2025, to be appointed as Lead Plaintiff. Pomerantz encourages affected investors to reach out to their office for further information about the legal process. Inquiries can be made via email at [email protected] or by calling 646-581-9980, where seeking legal advice is encouraged.

The Role of Pomerantz LLP

Pomerantz LLP has a strong history of advocating for investors' rights, particularly in cases involving securities fraud and corporate misconduct. Founded over 85 years ago by Abraham L. Pomerantz, the firm has established itself as a pioneer in the realm of securities class actions. Many of their legal victories have resulted in significant damage recoveries for members of various classes. They boast offices in major cities, including New York, Los Angeles, London, and Tel Aviv, assuring a broad reach and deep expertise in managing such complex litigation.

Conclusion: A Call to Action

As the deadlines for joining the class action draw near, it’s critical for investors in BioAge Labs, Inc. to be proactive. This may be an opportunity for those affected by the company's drastic stock decline to seek justice and possibly recover their investments. In an age where investor accountability is crucial, legal representatives like Pomerantz LLP play a vital role in ensuring that those harmed by corporate missteps are heard and compensated.

For more detailed updates, check the official Pomerantz law website.